At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
RNAC Cartesian Therapeutics
Trading 12-22 09:30:10 EST
7.23
+0.01
+0.14%
High7.23Low7.23Vol1.23K
Open7.23D1 Closing7.22Amplitude0.00%
Mkt Cap188.01MTradable Cap67.89MTotal Shares26.00M
T/O8.87KT/O Rate0.01%Tradable Shares9.39M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Cartesian Therapeutics Inc. Files Initial Statement of Beneficial Ownership for Director Adrian Ion Bot
Reuters  ·  12-19
Cartesian Therapeutics Inc. Files Initial Statement of Beneficial Ownership for Director Adrian Ion Bot
Cartesian Therapeutics Announces the Appointment of Adrian BOT to Board of Directors
THOMSON REUTERS  ·  12-19
Cartesian Therapeutics Announces the Appointment of Adrian BOT to Board of Directors
Press Release: Cartesian Therapeutics Announces the Appointment of Adrian Bot to Board of Directors
Dow Jones  ·  12-19
Press Release: Cartesian Therapeutics Announces the Appointment of Adrian Bot to Board of Directors
Independent Director of Cartesian Therapeutics Picks Up 168% More Stock
Simply Wall St.  ·  12-11
Independent Director of Cartesian Therapeutics Picks Up 168% More Stock
Director Timothy C. Barabe Acquires Common Shares of Cartesian Therapeutics Inc
Reuters  ·  12-09
Director Timothy C. Barabe Acquires Common Shares of Cartesian Therapeutics Inc
Strategic Pivot and Promising Clinical Data Justify Buy Rating for Cartesian Therapeutics
TIPRANKS  ·  11-22
Strategic Pivot and Promising Clinical Data Justify Buy Rating for Cartesian Therapeutics
Cartesian Therapeutics Announces Strong Efficacy Signal in Phase 2 Trial of Descartes-08 in Patients with SLE and Expansion of Clinical Development into Myositis
Reuters  ·  11-20
Cartesian Therapeutics Announces Strong Efficacy Signal in Phase 2 Trial of Descartes-08 in Patients with SLE and Expansion of Clinical Development into Myositis
Cartesian Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Dow Jones  ·  11-19
Cartesian Therapeutics Is Maintained at Buy by HC Wainwright & Co.
H.C. Wainwright cuts Cartesian target, calls shares ‘mispriced’
TIPRANKS  ·  11-19
H.C. Wainwright cuts Cartesian target, calls shares ‘mispriced’
Analysts Offer Insights on Healthcare Companies: Cartesian Therapeutics (RNAC) and Galmed Pharmaceuticals (GLMD)
TIPRANKS  ·  11-19
Analysts Offer Insights on Healthcare Companies: Cartesian Therapeutics (RNAC) and Galmed Pharmaceuticals (GLMD)
Analysts Offer Insights on Healthcare Companies: Athira Pharma (ATHA) and Cartesian Therapeutics (RNAC)
TIPRANKS  ·  11-17
Analysts Offer Insights on Healthcare Companies: Athira Pharma (ATHA) and Cartesian Therapeutics (RNAC)
Cartesian Pauses Lupus And Multiple Myeloma Studies As It Shifts Development Focus
Benzinga  ·  11-15
Cartesian Pauses Lupus And Multiple Myeloma Studies As It Shifts Development Focus
Wedbush Remains a Buy on Cartesian Therapeutics (RNAC)
TIPRANKS  ·  11-15
Wedbush Remains a Buy on Cartesian Therapeutics (RNAC)
Top Calls on Wall Street: Nvidia, Applied Materials, Nu Holdings, Lowe's, Shake Shack, Gap & More
Tiger Newspress  ·  11-15
Top Calls on Wall Street: Nvidia, Applied Materials, Nu Holdings, Lowe's, Shake Shack, Gap & More
Strategic Realignment Boosts Cartesian Therapeutics’ Prospects: Gil Blum Issues Buy Rating
TIPRANKS  ·  11-14
Strategic Realignment Boosts Cartesian Therapeutics’ Prospects: Gil Blum Issues Buy Rating
Cartesian Therapeutics Is Maintained at Buy by BTIG
Dow Jones  ·  11-14
Cartesian Therapeutics Is Maintained at Buy by BTIG
Cartesian Therapeutics price target raised to $44 from $42 at BTIG
TIPRANKS  ·  11-14
Cartesian Therapeutics price target raised to $44 from $42 at BTIG
Cartesian Therapeutics Reports Q3 2025 Financial Results
TIPRANKS  ·  11-14
Cartesian Therapeutics Reports Q3 2025 Financial Results
Cartesian Therapeutics Reports Promising Phase 2 Trial Results
TIPRANKS  ·  11-14
Cartesian Therapeutics Reports Promising Phase 2 Trial Results
Cartesian Therapeutics Inc - Cartesian Plans to Pause Further Development of Descartes-08 in Sle
THOMSON REUTERS  ·  11-14
Cartesian Therapeutics Inc - Cartesian Plans to Pause Further Development of Descartes-08 in Sle

Introduction

Company Name.
Cartesian Therapeutics
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Issue price:
--